65,437 trials
Infections, Streptococcal
Primary: Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes. — 0.48; 0.35; 0.56; 0.48 µg/mL
Maxillary Sinusitis
Primary: Percentage of Participants With Response of Very Convenient or Somewhat Convenient — 100.0; 72.9 Percentage of Participants — p=<0.0001
Pulmonary Disease, Chronic Obstructive
Primary: Success of Treatment With Tiotropium According to Physician's Assessment — 620; 618; 452; 412 Participants
HIV Infections
Primary: Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48 — 83.3; 91.8; 85.4 percentage of participants
Stress-related Changes in Inflammation
Primary: Serum ln(IL-6) — 0.054; 0.051 ln(pg/mL) — p=0.97
Prostatic Hyperplasia
Primary: Number of Participants Reporting Compliance With Medication — 239; 161 participants
Allergic Conjunctivitis
Primary: Ocular Itching — 1.48; 1.84; 1.82; 1.93 Units on a Scale
Staphylococcal Infections
Primary: Acquisition of Methicillin-resistant Staph Aureus (MRSA) Colonization or Infection — 9; 10 participants — p=>0.05
Actinic Keratoses
Primary: Patients With Complete Clearance of Actinic Keratosis (AKs) — 35; 6 Participants — p=<0.0001
Actinic Keratosis
Primary: Patients With Complete Clearance of Actinic Keratosis (AK) Lesions. — 50; 3 participants — p=0.001
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 26 — -1.28; -1.48 percentage of total hemoglobin — p=0.002
Diabetes · Foot Ulcers
Primary: Mean Change in Wound Area. — -33.7 cm2
Hypertension
Primary: Number of Patients With Cerebrovascular(CeV) and Cardiovascular (CaV) Events — 479; 19964 Number of participants
Metastatic Colorectal Cancer
Primary: Progression-Free Survival (PFS) — 9.1; 8.7 Months — p=0.2309
Neuromuscular Blockade
Primary: Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Rocuronium or Succinylcholine — -0.06; 0.30 mmol/L — p=<0.0001